Clinical Trial Update: Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating guadecitabine (SGI-110) vs treatment choice in adults with myelodysplastic syndromes or chronic myelomonocytic leukemia previously trea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Guadecitabine (SGI-110) (guadecitabine)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2023-05-18